(CercleFinance.com) – Genfit posted cash and cash equivalents of 93.9 million euros as of September 30, compared to 111.8 million at the end of June, a decrease which notably takes into account its sustained research and development’.
The biopharmaceutical company expects its cash and equivalents to fund its operational and capital expenditures through, approximately, the fourth quarter of 2024, based on current assumptions.
Its turnover for the first nine months of 2023 amounted to 14.3 million euros, of which 9.1 million is linked to the partial recognition of the deferred income recognized upon signature of the agreement with Ipsen in December 2021.